CLDX Stock — Celldex Therapeutics Inc.: Cash, EV, Pipeline

Share price

$38.24

Market cap

$3,003.0M

Cash

$717.6M

Enterprise value

$2,285.4M

Balance sheet

Cash	$717.6M
Debt	$0.0M
Net cash	$717.6M
Enterprise value	$2,285.4M
Basic shares	78.5M shares
Fully diluted shares	91.4M shares
Fully diluted market cap	$3,493.2M
Cash per share	$9.14

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading CLDX daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Nov 12 - Dec 24	barzolvolimab	Phase 3	Chronic Spontaneous Urticaria	September 2026
Nov 12 - Dec 24	barzolvolimab	Phase 3	Chronic Spontaneous Urticaria	—
Apr 12 - May 24	CDX-622	Phase 1	Mild to Moderate Asthma	—
May 12 - Jun 23	Human CMV pp65-LAMP mRNA-pulsed autologous DCs	Phase 2	Glioblastoma	—
Jul 13 - Aug 24	Barzolvolimab	Phase 3	Chronic Inducible Urticaria; Cold Urticaria; Cold-Induced Urticaria	—
Oct 13 - Nov 24	barzolvolimab	Phase 3	Chronic Spontaneous Urticaria	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Barzolvolimab

Phase 3 · Active Modality: humanized monoclonal antibody (subcutaneous)

Aliases CDX-0159

Target KIT

Indications

Chronic spontaneous urticaria (CSU) (Phase 3)
Chronic inducible urticaria (ColdU / symptomatic dermographism) (Phase 3)
Atopic dermatitis (Phase 2)

Catalysts

— September/October 2026
— late 2026

Status note CSU Phase 3 enrollment complete (1,939 pts); ColdU/SD Phase 3 initiated Dec 2025, enrolling. PN Phase 2 discontinued Jul 2026 after missing primary/key secondary endpoints (mast cells may not be key pathogenic driver in PN). $52.5M regulatory-approval milestone to former Kolltan holders on first FDA/EMA approval of a surviving product.

CDX-622

Phase 1 · Active Modality: bispecific antibody

Target TSLP / SCF

Indications

Asthma (mild-to-moderate) (Phase 1)

Status note First bispecific candidate (TSLP x SCF); Phase 1a in healthy volunteers (enrollment complete Jan 2026) plus open-label Phase 1 proof-of-mechanism study in mild-to-moderate asthma initiated Jan 2026.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	barzolvolimab
Lead indication	Chronic Spontaneous Urticaria
Lead phase	Phase 3
Active trials	7
Collaborator trials	6

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06445023	Phase 3	Active, not recruiting	Sponsor	CLDX	—	Chronic Spontaneous Urticaria	September 2026
NCT06455202	Phase 3	Active, not recruiting	Sponsor	CLDX	—	Chronic Spontaneous Urticaria	—
NCT07266402	Phase 3	Recruiting	Sponsor	CLDX	—	Chronic Inducible Urticaria; Cold Urticaria; Cold-Induced Urticaria	—
NCT07256392	Phase 3	Enrolling by invitation	Sponsor	CLDX	—	Chronic Spontaneous Urticaria	—
NCT06366750	Phase 2	Active, not recruiting	Sponsor	CLDX	—	Prurigo Nodularis	—
NCT06727552	Phase 2	Active, not recruiting	Sponsor	CLDX	—	Atopic Dermatitis	—
NCT07330778	Phase 1	Recruiting	Sponsor	CLDX	—	Mild to Moderate Asthma	—
NCT03804944	Phase 2	Recruiting	Collaborator	Weill Medical College of Cornell University	MRK	Breast Cancer	—
NCT05231122	Phase 2	Recruiting	Collaborator	Roswell Park Cancer Institute	MRK	Ovarian Clear Cell Adenocarcinoma; Platinum-Sensitive Ovarian Carcinoma; Recurrent Endometrial Serous Adenocarcinoma	—
NCT03688178	Phase 2	Active, not recruiting	Collaborator	Annick Desjardins, MD	—	Glioblastoma	—
NCT05349890	Phase 1	Active, not recruiting	Collaborator	Providence Health & Services	—	Malignant Epithelial Neoplasms	—
NCT04930783	Phase 1	Active, not recruiting	Collaborator	Dana-Farber Cancer Institute	—	Melanoma; Metastatic Melanoma	—

Sponsor-matched active trials from ClinicalTrials.gov (7 as sponsor, 6 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 13 active trials for Celldex Therapeutics on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Logos Global Management	2,100,000	+1,650,000	3.36%	2026-08-14
Baker Bros. Advisors	1,182,611	+517,241	0.22%	2026-08-14
ADAR1 Capital Management	619,542	+191,726	1.08%	2026-08-14
Ikarian Capital	478,500	+17,253	2.91%	2026-08-14
Braidwell LP	436,646	-919,436	0.60%	2026-08-14
Sphera Biotech	240,868	-2,707	1.28%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

CLDX — Celldex Therapeutics Inc.